Giuseppe Biondi Zoccai University of Turin, Turin, Italy

Slides:



Advertisements
Similar presentations
Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino
Advertisements

Name of the speaker: Germano DiSciascio I have the following potential conflicts of interest to report: Consulting Employment in industry Stockholder of.
J. Mehilli, A. Kastrati, K. Huber, S. Schulz, J. Pache, C.Markwardt, S. Kufner, F. Dotzer, K. Schlotterbeck, J. Dirschinger, A. Schömig. Abciximab in Patients.
Keith A A Fox Royal Infirmary & University of Edinburgh CURE and PCI-CURE.
STENT THROMBOSIS: WHICH IMPACT IN REAL CLINICAL PRACTICE? Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino Ospedale S. Giovanni Battista.
Canadian Diabetes Association Clinical Practice Guidelines Acute Coronary Syndromes and Diabetes Chapter 26 Jean-Claude Tardif, Phillipe L. L’Allier, David.
Prasugrel vs ticagrelor in acute coronary syndromes
Khawar Kazmi. Thrombosis LipidsInflammation Thrombus Platelets and thrombin Quiescent Plaque Plaque rupture PATHOGENESIS ACUTE CORONARY SYNDROME.
Pharmacology in Acute Coronary Syndromes: Anti-platelet Agents Tim Kinnaird, University Hospital Wales, Cardiff and Vale NHS Trust.
Prescribing Information is available at the end of this presentation NHS Surrey Lipid Guidelines Dr Adam Jacques Ashford & St.
TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.
Novel antithrombotic agents in acute coronary syndromes: better or worse than P2Y12 inhibitors Giuseppe Biondi Zoccai Sapienza Università di Roma
Prasugrel Compared to Clopidogrel in Patients with Acute Coronary Syndromes Undergoing PCI with Stenting: the TRITON - TIMI 38 Stent Analysis Stephen D.
Clopidogrel in ACS: Overview Investigator, TIMI Study Group Associate Physician, Cardiovascular Division, BWH Assistant Professor of Medicine, Harvard.
The Landscape of Oral Antiplatelet Agents 2009 George D. Dangas, MD, PhD, FSCAI, FACC Associate Professor of Medicine Columbia University Medical Center.
CURRENT PUBLICATION TRENDS IN INTERVENTIONAL CARDIOLOGY Giuseppe Biondi Zoccai Division of Cardiology, University of Turin, Turin, Italy.
C.R.E.D.O. C lopidogrel for the R eduction of E vents D uring O bservation Multicenter Multinational (USA, Canada) Prospective Randomized Double Blind.
ACUTE CORONARY SYNDROMES:
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Clopidogrel Pretreatment Versus Clopidogrel Exposure Prior to PCI in the ACUITY Trial: Does it Really Matter? Steven R. Steinhubl, Frederick Feit, Antonio.
Robert F. Storey Senior Lecturer and Honorary Consultant in Cardiology, University of Sheffield, Sheffield, UK Stent thrombosis Future directions.
Stents Are Not Enough: Recent Clopidogrel Data Rob Henderson Nottingham City Hospital Rob Henderson Nottingham City Hospital.
Applications of bivalirudin in interventional cardiology
Aspirin Resistance: Significance, Detection and Clinical Management of This Real Phenomenon Webcast May 10 th, 2004 Sponsored by.
Objective:To assess the effect of various clopidogrel and aspirin regimens on major CV events and ST in ACS patients undergoing PCI. Study:Multicenter,
Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.
MANAGING ATHERO- THROMBOTIC RISK Early impact and long-term benefit of antiplatelet therapy What is the optimal duration of antiplatelet therapy? Giuseppe.
Antiplatelet therapy and PCI in unstable angina and NSTEMI Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino
Giuseppe Biondi Zoccai University of Turin, Turin, Italy METCARDIO, Turin, Italy JOINT SYMPOSIUM WITH JACCT - Bologna, 25/9/2008.
PRACTICAL RECOMMENDATIONS ON ANTI- THROMBOTIC TREATMENT IN PATIENTS TREATED WITH DRUG-ELUTING STENTS Giuseppe Biondi-Zoccai Ospedale S. Giovanni Battista.
TRITON TIMI-38 STEMI cohort Primary End Point (CV death, MI and stroke at 15 months) Adapted from Montalescot et al. ESC Time (days)
Giuseppe Biondi Zoccai University of Turin, Turin, Italy METCARDIO, Turin, Italy BMS & Sanofi Aventis Sponsored.
TRITON TIMI-38 STEMI cohort Clopidogrel Under Fire: Is Prasugrel in Primary PCI or Recent MI Superior? Insights From TRITON-TIMI-38 Gilles Montalescot,
Date of download: 5/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: The thrombolysis in myocardial infarction risk score.
Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.
Prasugrel in all ACS Patients! Giuseppe Biondi-Zoccai, MD Sapienza University of Rome, Italy
Heparin Should be the First-line Therapy for Patients with ACS/AMI
Stent Thrombosis and Optimal Duration of DAPT
The American College of Cardiology Presented by Dr. Adnan Kastrati
MCV Campus Ginger Edwards.
Should We Preload STEMI Patients with Antiplatelet Therapy?
Clinical need for determination of vulnerable plaques
Matthew J. Price MD Director, Cardiac Catheterization Laboratory,
The European Society of Cardiology Presented by Dr. Saman Rasoul
The GRAVITAS trial Matthew J. Price MD, FACC, FSCAI
The Big Antiplatelet Debate Why I Prefer Prasugrel Over Ticagrelor
The DANAMI-2 Trial Danish Trial in Acute Myocardial Infarction-2
The ANTARCTIC investigators
ATLANTIC Trial design: Participants with STEMI being transported for primary PCI were randomized in the ambulance to ticagrelor 180 mg (n = 909) vs. placebo.
Giuseppe Biondi Zoccai
Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial
Diabetes mellitus in patients undergoing percutaneous drug-eluting stent implantation: short and long-term results Claudio Moretti, M.D. Division of Cardiology,
Late Breaking Clinical Trials
Eugene Braunwald, MD, Marc S. Sabatine, MD, MPH 
American Heart Association Presented by Dr. Julinda Mehilli
SURGERY EARLY AFTER DES IMPLANTATION
Benefits of complete coronary revascularization – Counterpoint: what are you talking about? Giuseppe Biondi Zoccai, MD University of Modena and Reggio.
Emerging Data Regarding the Potential Benefits of Early Initiation of Clopidogrel Among ACS Patients C. Michael Gibson, M.S., M.D.
What oral antiplatelet therapy would you choose?
Single Versus Multiple Vessel Stenting In Patients With St-Elevation Myocardial Infarction: Results From A 30,886-Patient Meta-Analysis Giuseppe Biondi.
ARISE Trial Aggressive Reduction of Inflammation Stops Events
Efficacy and Safety of Fondaparinux in Elderly Patients With ST-Segment Elevation Myocardial Infarction: Data From the OASIS 6 Trial Ron J.G. Peters,
Comparison of radial versus femoral access in patients undergoing invasive management for acute coronary syndromes: evidence from a systematic review and.
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
OASIS-5: Study Design Randomize N=20,078 Enoxaparin (N=10,021)
Is Prasugrel Superior To Ticagrelor For The Treatment Of Patients With Acute Coronary Syndromes? Evidence From A 32,893-Patient Adjusted Indirect Comparison.
SOLID-TIMI 52 Trial design: Participants within 30 days of an acute coronary syndrome (ACS) were randomized to darapladib 160 mg daily (n = 6,504) versus.
The Case for Routine CYP2C19 ( Plavix® ) Genetic Testing
Section C: Clinical trial update: Oral antiplatelet therapy
Cardiovascular Epidemiology and Epidemiological Modelling
Presentation transcript:

THE CURRENT CLOPIDOGREL LOADING DOSE: IRRELEVANT, TOO LOW, OR TOO LATE? Giuseppe Biondi Zoccai University of Turin, Turin, Italy METCARDIO, Turin, Italy gbiondizoccai@gmail.com Consensus in Cardiologia: Cardiologi a confronto sull’aterotrombosi Roma, 20/6/2008 – 9.00-9.20

DISCLOSURE Consultant: Boston Scientific, Cordis, genae, Invatec, Mediolanum Cardio Research Lecture fees: Bristol-Myers Squibb, Sanofi Aventis Research grants: AIFA

LEARNING GOALS What is the currently approved loading dose of clopidogrel and why? Is it worthwhile to increase the clopidogrel loading dose? Is it worthwhile to anticipate the loading dose?

LEARNING GOALS What is the currently approved loading dose of clopidogrel and why? Is it worthwhile to increase the clopidogrel loading dose? Is it worthwhile to anticipate the loading dose?

RESHAPING THE EVIDENCE BASE IS CHALLENGING 300 MG LOADING: IMMEDIATELY IN ACS OR >6 HOURS BEFORE PCI

Steinhubl et al, JAMA 2002;288:2411-20 THE CREDO TRIAL Steinhubl et al, JAMA 2002;288:2411-20

THE CURE TRIAL N=12,562 patients with unstable angina or non-ST-elevation myocardial infarction 20% RRR p=0.00009 0.00 0.02 0.04 0.06 0.08 0.10 0.12 0.14 Placebo + ASA Cumulative hazard rate of CV death, MI or stroke Clopidogrel 300 mg loading and then 75 mg/d + ASA 3 6 9 12 Yusuf et al, NEJM 2001;345:494-502

THE CLARITY-TIMI 28 TRIAL Sabatine et al, NEJM 2005;352:1179-89

COMMIT Investigators, Lancet 2005;366:1607-21 THE COMMIT TRIAL COMMIT Investigators, Lancet 2005;366:1607-21

LEARNING GOALS What is the currently approved loading dose of clopidogrel and why? Is it worthwhile to increase the clopidogrel loading dose? Is it worthwhile to anticipate the loading dose?

WHEN IS MUCH TOO MUCH?

Von Beckerath et al, Circulation 2005;112:2946-50 600 or 900 MG LOADING? Von Beckerath et al, Circulation 2005;112:2946-50

Von Beckerath et al, Circulation 2005;112:2946-50 600 or 900 MG LOADING? Von Beckerath et al, Circulation 2005;112:2946-50

Montalescot et al, J Am Coll Cardiol 2006;48:931-8 600 or 900 MG LOADING? Montalescot et al, J Am Coll Cardiol 2006;48:931-8

600 MG LOADING IN STABLE PATIENTS – THE ISAR-REACT TRIAL 600 mg of clopidogrel at least 2 hours before PCI Kastrati et al, NEJM 2004;350:232-8

600 MG LOADING IN UNSTABLE PATIENTS – THE ISAR-REACT 2 TRIAL Kastrati et al, JAMA 2006;295:1531-38

600 MG LOADING IN AMI – THE BRAVE-3 STUDY p>0.05 % p>0.05 Mehilli et al, ACC 2008

600 MG RELOADING: THE ARMYDA-RELOAD TRIAL Patients on 75 mg/d of clopidogrel for >10 days 9 6.8 % 0.5 Placebo 600 mg Clopidogrel reload DiSciascio et al, ACC 2008

SUMMARY OF EVIDENCE ON CLOPIDOGREL LOADING

SUMMARY OF EVIDENCE ON CLOPIDOGREL LOADING Lotrionte et al, Am J Cardio 2007;100:1199-1206

LEARNING GOALS What is the currently approved loading dose of clopidogrel and why? Is it worthwhile to increase the clopidogrel loading dose? Is it worthwhile to anticipate the loading dose?

WHEN IS EARLY TOO EARLY?

HOW LONG DOES IT TAKE FOR CLOPIDOGREL TO ACT? Hochholzer et al, Circulation 2005;111:2560-64

HOW LONG DOES IT TAKE FOR CLOPIDOGREL TO ACT? 600 mg -> 2 hours Hochholzer et al, Circulation 2005;111:2560-64

Steinhubl et al, JAMA 2002;288:2411-20 THE CREDO TRIAL Steinhubl et al, JAMA 2002;288:2411-20

THE CREDO TRIAL p=0.051 favoring 300 mg clopidogrel loading>6 hours before PCI Steinhubl et al, JAMA 2002;288:2411-20

DOES EARLY 300 MG PRETREATMENT OF STABLE PATIENTS MAKE SENSE?

DOES EARLY 600 MG PRETREATMENT OF STABLE PATIENTS MAKE SENSE?

ANTICIPATING LOADING IN STABLE PATIENTS Widimsky et al, Eur Heart J 2008;29:1495-1503

ANTICIPATING LOADING IN STABLE PATIENTS Widimsky et al, Eur Heart J 2008;29:1495-1503

ANTICIPATING LOADING IN STABLE PATIENTS Widimsky et al, Eur Heart J 2008;29:1495-1503

ANTICIPATING (AND INCREASING) LOADING IN UNSTABLE PATIENTS

ANTICIPATING (AND INCREASING) LOADING IN UNSTABLE PATIENTS Patients with ACS (UA/NSTEMI or STEMI) planned for early invasive strategy, i.e. intend for PCI as early as possible within 72 hrs of randomization RANDOMIZE Clopidogrel High Dose Group Clopidogrel 600mg loading dose Day 1 followed by 150mg from Day 2 to Day 7; then 75mg from Day 8 to 30 Clopidogrel Standard Dose Group Clopidogrel 300mg (+placebo) Day 1 followed by 75mg (+placebo) from Day 2 to Day 7; 75mg from Day 8 to 30 RANDOMIZE RANDOMIZE ASA low dose group At least 300mg Day1; 75–100mg from D2 to D30 ASA high dose group At least 300mg Day1; 300mg–325mg from D2 to D30 ASA low dose group At least 300mg Day1; 75–100mg from D2 to D30 ASA high dose group At least 300mg Day1; 300mg–325mg from D2 to D30

TAKE HOME MESSAGES

TAKE HOME MESSAGES Several trials and guidelines support a clopidogrel loading dose of at least 300 mg A 600 mg loading dose is recommended in patients at high risk of ischemic events and low bleeding risk who are undergoing PCI These loading doses should be administered immediately at diagnosis in patients with acute coronary syndromes, and between 2 hours before and just before PCI in stable patients

For further slides on these topics please feel free to visit the metcardio.org website: http://www.metcardio.org/slides.html

RESERVE SLIDES

WHAT ABOUT OTHER DRUGS? THE PRINCIPLE-TIMI 44 Wiviott et al, Circulation 2007;116:2923-32

WHAT ABOUT OTHER DRUGS? THE PRINCIPLE-TIMI 44 Wiviott et al, Circulation 2007;116:2923-32

WHAT ABOUT OTHER DRUGS? THE TRITON-TIMI 38 Wiviott et al, Lancet 2008;371:1353-63

WHAT ABOUT OTHER DRUGS? THE TRITON-TIMI 38 Wiviott et al, Lancet 2008;371:1353-63

WHAT ABOUT OTHER DRUGS? THE TRITON-TIMI 38 Wiviott et al, Lancet 2008;371:1353-63